Cite this: *Chem. Sci.*, 2015, 6, 4978

Signal transduction and amplification through enzyme-triggered ligand release and accelerated catalysis†

Sean Goggins,^a Barrie J. Marsh,^b Anneke T. Lubben^a and Christopher G. Frost^{*a}

Signal transduction and signal amplification are both important mechanisms used within biological signalling pathways. Inspired by this process, we have developed a signal amplification methodology that utilises the selectivity and high activity of enzymes in combination with the robustness and generality of an organometallic catalyst, achieving a hybrid biological and synthetic catalyst cascade. A proligand enzyme substrate was designed to selectively self-immolate in the presence of the enzyme to release a ligand that can bind to a metal pre-catalyst and accelerate the rate of a transfer hydrogenation reaction. Enzyme-triggered catalytic signal amplification was then applied to a range of catalyst substrates demonstrating that signal amplification and signal transduction can both be achieved through this methodology.

Received 1st May 2015
Accepted 13th June 2015

DOI: 10.1039/c5sc01588j

www.rsc.org/chemicalscience

Introduction

In nature, living organisms utilise signal transduction and signal amplification for selective and amplified chemical responses towards particular stimuli.¹ These powerful systems are used for a number of purposes, such as visual excitation,² blood clotting,³ and biosignalling.⁴ Typically, these biological responses are realised through enzyme cascade mechanisms.⁵ Naturally, the high signal amplification and rapid response times of these systems have inspired the development of a range of versatile, synthetic signal amplification systems for stimuli-responsive materials,⁶ supramolecular signalling,⁷ and sensing.⁸ With regard to the latter, approaches towards signal amplification for sensing vary tremendously with nano-materials,⁹ conjugated polymers,¹⁰ and supramolecular aggregates,¹¹ all being successfully incorporated into analyte detection methodologies and achieving low limits of detection. Recently, the introduction of self-immolative dendrimers,¹² has propelled the development of small molecule-based signal amplification protocols.¹³ In particular, the dendritic chain reaction (DCR) developed by Sella and Shabat,¹⁴ and the two-component system developed by Baker and Phillips,¹⁵ have both demonstrated autoinductive and autocatalytic exponential signal amplification for the detection of a number of analytes.¹⁶

Despite the high amplification achieved and the thermal stability of the reagents, these methods suffer from high background reactions due to reagent hydrolysis and long reaction times.¹⁷ As such, there is still a need for stable and selective reagents that can provide rapid signal amplification.

The ability of catalysts to generate multiple product molecules without themselves being chemically altered has seen them integrated as the amplifier component within multiple signal amplification methodologies.¹⁸ Signal amplification by supramolecular catalysis (SAAC),¹⁹ has by far become the most popular catalytic approach to signal amplification due to the plethora of supramolecular analyte receptors and synthetic organometallic catalysts available that can be combined to create an effective amplified detection assay.²⁰ However, turnover numbers are inadequate and the assays often require the use of organic solvents under an inert atmosphere. Contrastingly, a range of iridium-based, water-soluble organometallic complexes have been synthesised and shown to perform a number of organic transformations “in- or on-water”.²¹ Iridium-catalysed transfer hydrogenation in particular, is of significant interest due to its low catalytic loading, fast reaction times and high substrate conversion.²² To the best of our knowledge, these outstanding catalyst attributes are yet to be harnessed for signal amplification within a sensing methodology. Herein, we describe an enzyme-triggered iridium-catalysed transfer hydrogenation for signal transduction and amplification.

Results and discussion

Concept

Inspired by biosignalling enzyme cascades, we designed an enzyme-activated synthetic catalyst cascade that could be used for signal transduction and signal amplification purposes

^aDepartment of Chemistry, University of Bath, Bath, BA2 7AY, UK. E-mail: C.G.Frost@bath.ac.uk; Fax: +44 (0)1225 386231; Tel: +44 (0)1225 386142

^bAtlas Genetics, Derby Court, Epsom Square, White Horse Business Park, Trowbridge, Wiltshire, BA14 0XG, UK. E-mail: barrie.marsh@atlasgenetics.com; Tel: +44 (0)1225 717932

† Electronic supplementary information (ESI) available: Experimental procedures, compound characterisation data and copies of NMR spectra for novel compounds. See DOI: 10.1039/c5sc01588j

Fig. 1 Signal amplification concept through enzyme-triggered ligand release and subsequent ligand-accelerated organometallic catalysis.

(Fig. 1). In principle, this would combine the selectivity and high activity of an enzyme plus add the control and scope of a synthetic catalyst. To gain proof of concept, we initially looked into identifying an efficient catalyst that we could employ as both our signal transducer and signal amplifier. Also, we required a catalyst that could be selectively switched on in the presence of an enzyme. One catalytic system that we believed fulfilled these criteria was an iridium-based transfer hydrogenation catalyst, which has been shown to efficiently reduce aldehydes in aqueous media.²² Not only this, but the addition of a ligand was shown to increase the turnover frequency (TOF) of the catalyst 600-fold, which we could potentially manipulate for catalyst activation.

To begin our investigation, we looked to use an electroactive aldehyde as the catalyst substrate as this would allow reaction progress to be monitored 'real-time' through simple electrochemical analysis without the need for compound extraction or isolation. The stability of ferrocene in aqueous media, its compatibility with biological components and its favourable electrochemical properties made ferrocenecarboxaldehyde **1** an obvious initial choice.²³ Electrochemical analysis of **1**, and its corresponding reduced product, ferrocenemethanol **2**, using

differential pulse voltammetry (DPV), revealed that aldehyde **1** and alcohol **2** have considerably different oxidation potentials ($\Delta E_{\text{ox}} \approx 300$ mV) (Fig. 2). As no peak overlap was observed, peak integration could be used to calculate reaction conversion allowing reaction progress to be monitored using ratiometric electrochemical analysis. Ratiometric sensing has the benefit of obtaining reaction conversions without internal or external standards, and also minimises errors associated with sampling and electrode or instrument variations. Thus, the reaction conversion of the transfer hydrogenation reaction can be calculated using eqn (1).

Pleasingly, when the literature conditions were applied to ferrocenecarboxaldehyde **1**, the product, ferrocenemethanol **2**, was isolated in 71% yield. By increasing the catalytic loading and introducing an enzyme-compatible, water-miscible co-solvent to improve the solubility of the substrate, quantitative yield was achieved in just 30 minutes at room temperature. In order to further improve catalytic activity under the optimised conditions we synthesised and tested a range of ligands with varying aryl substituents (ESI†). Only mesityl-derivative **L4** provided any improvement over the previously-used tosyl-derivative and was subsequently used in all further studies. Importantly, in the absence of any ligand, minimal conversion was observed, highlighting the importance of a ligand in order to achieve high catalytic activity (Table S1†). Thus, we hypothesised that a programmed, selective release of the ligand would accelerate the transfer hydrogenation reaction in the presence of an enzyme.

$$\text{Conversion (\%)} = \left(\frac{\int 2}{(\int 1 + \int 2)} \right) \times 100 \quad (1)$$

Ligand functionalisation studies towards proligand design

Enzyme-triggered compound release is typically associated with prodrug methodologies, where active pharmaceutical ingredients are manipulated with enzyme-responsive functional groups to improve their physical properties as well as their potency.²⁴ We therefore reasoned that we could combine an enzyme-cleavable trigger moiety with a self-immolative linker to design a proligand which would selectively release our optimised ligand in the presence of an enzyme. To achieve a successful proligand, we first required further information regarding the essential components and the limitations of the ligand. Therefore, we synthesised (ESI†) another set of ligand derivatives and tested them under the optimised reaction conditions (Table 1).

Ethylenediamine, along with its mono- and di-methylated derivatives (Table 1, entries 1–4) were all found to be ineffective ligands under these conditions. Also, tetramethylethylenediamine (Table 1, entry 5) was shown to completely inhibit the reaction. Expectedly, the best-performing ligand deduced from the optimisation, mono-mesityl sulfonamide **L4** (Table 1, entry 6), delivered quantitative conversion in 30 minutes, confirming that a sulfonamide is required for a high reaction rate. Methylation at the primary amine position of **L4** (Table 1, entry 7),

Fig. 2 Differential pulse voltammogram obtained for a mixture of 0.25 mM ferrocenecarboxaldehyde **1** and 0.25 mM ferrocenemethanol **2**.

Table 1 Ligand derivative screen

		L11, R ¹ = R ² = R ³ = R ⁴ = H
		L12, R ¹ = Me, R ² = R ³ = R ⁴ = H
		L13, R ¹ = R ² = Me, R ³ = R ⁴ = H
		L14, R ¹ = R ³ = Me, R ² = R ⁴ = H
		L15, R ¹ = R ² = R ³ = R ⁴ = Me
		L4, R ⁵ = R ⁶ = R ⁷ = H
		L16, R ⁵ = Me, R ⁶ = R ⁷ = H
		L17, R ⁵ = R ⁶ = H, R ⁷ = Me
		L18, R ⁵ = R ⁶ = Me, R ⁷ = H
		L19, R ⁵ = R ⁷ = Me, R ⁶ = H
		L20, R ⁸ = <i>t</i> Bu
		L21, R ⁸ = Bn
		L22, R ⁸ = 4-MeOBn

Entry	Ligand	Conversion ^a
1	L11	2%
2	L12	2%
3	L13	<1%
4	L14	2%
5	L15	0%
6	L4	>99%
7	L16	34%
8	L17	6%
9	L18	0%
10	L19	0%
11	L20	7%
12	L21	<1%
13	L22	2%

^a Determined by ratiometric electrochemical analysis.

leads to a drop-off in conversion but interestingly, does not inhibit the reaction completely. Since a proton is still available at this position to activate the carbonyl towards attack of the hydride, this result corresponds with a typical transfer hydrogenation reaction mechanism.²⁵ Methylation of the sulfonamide of **L4** (Table 1, entry 8) however, leads to a significantly greater drop-off in conversion as functionalisation at this position removes the acidic sulfonamide proton required for iridium insertion to form the active catalyst. Unsurprisingly therefore, both dimethyl derivatives of **L4** (Table 1, entries 9 and 10) completely inhibit the transfer hydrogenation reaction with no conversion at all observed. Clearly, as functionalisation at the primary amine position of **L4** was enough to prevent ligand acceleration of the catalyst, we next looked at ligands with alternative functionality at this position. Protecting the primary amine position as a carbamate (Table 1, entries 11–13), was indeed found to have a detrimental impact on reaction conversion. Interestingly, benzyl carbamate derivatives **L21** and **L22** exhibit minimal conversion in the transfer hydrogenation

reaction, leading us to believe that we could release ligand **L4** through a quinone-methide elimination mechanism.²⁶

Proligand synthesis and mechanistic studies

Consequently, proligand **PL1** was designed (Scheme 1) containing a benzyl carbamate linkage along with a phosphate functional group as the enzyme-cleavable trigger. A phosphate trigger enables **PL1** to be an appropriate enzyme substrate for alkaline phosphatase (ALP, EC 3.1.3.1), chosen for its high catalytic activity, robustness and inexpensive cost.²⁷ ALP is also a target of interest since abnormal serum levels can be used to preliminarily diagnose diseases such as bone disease,²⁸ liver dysfunction,²⁹ breast and prostatic cancer,³⁰ and diabetes.³¹ Moreover, ALP is commonly used as an enzyme label within enzyme-linked immunosorbent assays (ELISA) due to its ease of antibody conjugation allowing for this signal amplification methodology to be applied to sensitive protein detection.³²

The mechanism we propose for this signal amplification methodology is illustrated in Scheme 1. Initially, selective dephosphorylation of **PL1** by the enzyme ALP should occur and the resulting phenol intermediate would be unstable in the alkaline buffered conditions preferred by the enzyme. Subsequent 1,6-elimination should then take place releasing carbon dioxide, quinone methide **3** and ligand **L4**. Complexation of the newly released ligand with the iridium precatalyst would generate the active transfer hydrogenation catalyst **4** and an accelerated conversion of aldehyde to alcohol should then be observed.

The synthesis of **PL1** (Scheme 2) was achieved through 1,1'-carbonyldiimidazole (CDI) coupling of previously reported benzyl alcohol **5**,³³ and **L4** to afford diallyl-protected carbamate **6**. Allyl deprotection was then performed through the use of a polymer-bound palladium catalyst under reductive conditions and subsequent sodium salt formation furnished proligand **PL1** in 64% overall yield. Once isolated, **PL1** was found to be an air-stable solid which can be stored in a vial at room temperature for several months with any sign of degradation.

To determine whether proligand **PL1** is an appropriate substrate for ALP, **PL1** was subjected to a buffered solution containing ALP and the interaction monitored by ³¹P NMR (Fig. 3). Over time, **PL1** was shown to be completely consumed by the enzyme and simultaneously, the appearance of another peak corresponding to the phosphate anion, indicated that enzyme-catalysed hydrolysis of the reagent was indeed occurring. In another experiment, this time in the absence of the enzyme, the phosphate peak was not observed showing that **PL1** is stable towards background hydrolysis and that phosphate cleavage occurs selectively in the presence of the enzyme. Due to the need for a proton-saturated buffer solution and the poor solubility of the ligand **L4** in an aqueous solution, we were unable to detect the free ligand, or any elimination products by ¹H NMR.

In order to detect the elimination products, we studied the reaction using direct infusion Electrospray Time-of-Flight mass spectrometry (ESI-UHR-TOF MS, negative ion mode). Initially, an aqueous solution of **PL1** was monitored over a ten minute

Scheme 1 Proposed mechanism for enzyme-triggered ligand release and subsequent ligand-accelerated transfer hydrogenation.

Scheme 2 Synthetic route to PL1.

time-frame and in this period, only the ion corresponding to the $[M - H]^-$ of PL1 was observed, and no ion corresponding to ligand L4 was seen (ESI – Fig. S2†). This confirms the stability of PL1 to hydrolysis. Then, immediately after the addition of a solution of ALP, the appearance of the $[M - H]^-$ ion corresponding to L4 is seen and this ion is shown to increase with intensity over time (Fig. 4). Concomitantly, the enzyme substrate ion decreases in intensity, indicating that enzyme-catalysed consumption of PL1 and simultaneous production of L4 is occurring. Additionally, $[M - H]^-$ ions relating to eliminated linker 3 and 4-hydroxybenzyl alcohol, a result of quinone methide 3 being trapped by water, are also observed and intensities for these ions increase slowly over time (ESI – Fig. S3†). Over the course of the experiment, the $[M - H]^-$ ion

Fig. 3 Stacked ^{31}P NMR plots of PL1 after addition of ALP.

for the phenol intermediate was never observed. This suggests that elimination to L4 and 3 occurs rapidly under the reaction conditions. Together, this data confirms that both dephosphorylation of PL1 and subsequent elimination to release L4 occurs selectively in the presence of enzyme, which supports the enzyme-triggered catalyst activation mechanism we propose.

Enzyme-triggered catalysis

Having established that ligand release occurs selectively as a direct result of enzyme activity, a number of background reactions were performed to determine if catalyst activation is attributed to the combination of the presence of the enzyme and the enzyme substrate (Table 2). In the presence of just the enzyme and no PL1 (Table 2, entry 1), no conversion of 1 to 2 was observed showing that any ligand-like amino acid side-chains on the enzyme itself or any enzyme additives such as amino alcohol-derived stabilisers do not contribute to any

Fig. 4 Reaction profile of PL1 after addition of ALP monitored by mass spectrometry.

Table 2 Ligand derivative screen

Entry	Proligand	ALP	Yield ^a
1	0 mol%	100 U mL ⁻¹	0%
2	2 mol%	0 U mL ⁻¹	4%
3	2 mol%	100 U mL ⁻¹	95%

^a Isolated yield.

undesired reduction. In the absence of the enzyme, a satisfactorily low yield of ferrocenemethanol **2** was obtained in the presence of just the proligand (Table 2, entry 2). Gratifyingly, in the presence of both the enzyme and the proligand (Table 2, entry 3), a near quantitative yield was obtained which we attribute to enzyme-triggered ligand release and ligand-accelerated catalytic transfer hydrogenation.

With catalyst activity shown only to be activated by both the enzyme and the enzyme substrate, we next wanted to optimise the signal amplification cascade using ratiometric electrochemical analysis to monitor the cascade. Prior to this however, electrochemically-derived reaction profiles were needed for the active catalytic species in order to determine the lowest catalytic loading required to obtain full conversion in the shortest amount of time. As such, ferrocenecarboxaldehyde **1** was exposed to different catalytic loadings and the reaction was sampled every 3 minutes (Fig. 5). At a catalyst loading of 0.5 mol%, only $\approx 50\%$ conversion was observed after 30 minutes. By doubling the catalyst loading to 1 mol%, quantitative conversion was able to be obtained within the same timeframe. Doubling the catalytic loading further to 2 mol% enabled quantitative conversion to be achieved in less than 6 minutes.

Fig. 5 Electrochemically-determined reaction profiles under different catalytic loadings of active catalyst **4**.

Encouraged by the efficiency of the transfer hydrogenation of **1** at the higher catalyst loading, we set to electrochemically monitor enzyme activity over time (Fig. 6). Pleasingly, in the presence of high concentrations of ALP, conversion of **1** to **2** was indeed observed. The sigmoidal shape of the conversion curves indicate a slow catalyst-activation induction period is apparent until a sufficient number of iridium complexes have been activated which leads to a pseudo-exponential increase in conversion. A number of signal amplification methodologies previously reported exhibit sigmoidal reaction profiles that are indicative of an exponential-like mechanism being in effect.^{14a,15a,34} Importantly, in the absence of the enzyme, a minimal background reaction was observed showing that activation of the catalytic cascade occurs selectively. This further enhances the potential of this methodology since no protection, separation or manipulation of the reagents is required to achieve successful activation of the catalytic cascade.

To improve the efficiency of the signal amplification cascade further, we increased the temperature of the system to coincide with the optimum working temperature of the enzyme.³² This would not only increase the rate of **PL1** consumption but also increase the rate of the transfer hydrogenation reaction, thus leading to a much improved signal-amplified response. Indeed, at these elevated temperatures, much greater conversions were observed in comparison to the conversions obtained for the same enzyme concentration at room temperature (Fig. 7). A high concentration of ALP at 37 °C allows for quantitative conversion of the transfer hydrogenation reaction to be obtained within 15 minutes. Good conversions are also seen at lower enzyme concentrations indicating both the excellent sensitivity and good dynamic range of the catalytic cascade. However, the increase in temperature also leads to an increase in the background rate, which is expected since ligand-less iridium pre-catalysts are known to catalyse the transfer hydrogenation reaction.^{22a} Using

Fig. 6 Electrochemically-determined reaction profiles under different concentrations of ALP at room temperature.

the conversions obtained under these conditions after 3 minutes, a calibration curve was plotted (ESI†). From this, a limit of detection for this methodology was calculated to be 7.6 pM after a reaction time of 3 minutes which is comparable with that of redox cycling-based amplification methodologies for rapid electrochemical ALP detection.³⁵

Fig. 7 Electrochemically-determined reaction profiles under different concentrations of ALP at 37 °C.

Table 3 Aldehyde substrate scope

		Conversion ^a	
		ALP	
Entry	Product	0 U mL ⁻¹	25 U mL ⁻¹
1 ^b	<chem>c1ccc(cc1)CO</chem> 7	10%	>99%
2 ^b	<chem>c1ccc2cc3ccccc3cc2cc1CO</chem> 8	2%	77%
3 ^b	<chem>c1ccc2cc3cc4ccccc4cc3cc2cc1CO</chem> 9	2%	95%
4 ^c	<chem>Fc1ccc(cc1)CO</chem> 10	4%	>99%
5 ^c	<chem>FC(F)(F)c1ccc(cc1)CO</chem> 11	20%	>99%
6 ^c	<chem>O=[N+]([O-])c1ccc(cc1)CO</chem> 12	21%	>99%
7 ^b	<chem>COc1ccc(cc1)CO</chem> 13	11%	>99%
8 ^b	<chem>Oc1ccccc1CO</chem> 14	13%	>99%
9 ^b	<chem>CC(C)c1ccc(cc1)CO</chem> 15	14%	>99%
10 ^b	<chem>O=Cc1ccc(cc1)CO</chem> 16	26%	>99% ^d
11 ^b	<chem>CCCCC(C)CO</chem> 17	24%	>99%

Table 3 (Contd.)

Entry	Product	Conversion ^a	
		ALP	
		0 U mL ⁻¹	25 U mL ⁻¹
12 ^b	18	8%	75%

^a Conversion determined by ¹H NMR. ^b Reaction conditions: 0.25 mol% [Ir(cp*Cl₂)₂], 0.5 mol% PL1, 25 U mL⁻¹ ALP, 0.5 mmol R-CHO, 5 eq. NaOOCH, 1 mL EtOH, 1 mL pH 9.8 CO₃²⁻ buffer, 37 °C, 30 min.

^c Reaction conditions: 0.25 mol% [Ir(cp*Cl₂)₂], 0.5 mol% PL1, 25 U mL⁻¹ ALP, 1 mmol R-CHO, 5 eq. NaOOCH, 2 mL EtOH, 2 mL pH 9.8 CO₃²⁻ buffer, 37 °C, 30 min. ^d Combined conversion of 20 (75%) and 1,4-benzenedimethanol (25%).

Substrate scope

We next wanted to determine if the catalyst cascade could be applied to the enzyme-triggered reduction of aldehydes other than ferrocenecarboxaldehyde. Therefore, the optimised conditions were then directly applied to a range of different aldehydes (Table 3). Initially, we looked at catalyst substrates that could also be used to monitor reaction progress, and therefore enzyme activity, by means other than electrochemistry. First, we evaluated fluorophore-containing aldehydes (Table 3, entries 1–3) as this would allow signal transduction from enzyme activity to fluorescence to be obtained. Pleasingly, all fluorescent aldehydes tested delivered good to quantitative conversions in the presence of ALP, whilst maintaining a satisfactorily low background in its absence. Next, we investigated fluorine-containing aromatic aldehydes (Table 3, entries 4–6), which would enable ¹⁹F NMR to be used to monitor reaction progress. Again, good to quantitative conversions were obtained using these benzaldehydes. Electron-withdrawing substituents upon the aromatic ring (Table 3, entries 5–6) were found to over-activate the aldehyde towards hydride attack and a subsequent increase in background reaction is observed. In contrast, electron-donating groups (Table 3, entries 7–8) were able to suppress this background reaction. Interestingly, when a di-aldehyde was used as the catalyst substrate (Table 3, entry 10), the mono-hydrogenated product was found to be the major product over the di-hydrogenated product in a 3 : 1 ratio. Aliphatic aldehydes (Table 3, entry 11) are also tolerated, but an undesirably high background was observed which we attribute to the high solubility of the substrate in the reaction medium. Cinnamaldehydes are also reduced efficiently (Table 3, entry 12) in the presence of ALP with no alkene reduction being observed.

On the whole, signal transduction from enzyme activity to a range of output signals was successfully performed whilst maintaining sufficiently low signals in the absence of ALP. Despite this, we are currently investigating methods to nullify the background rate to improve the signal-to-noise ratio. Also, the application of this catalyst cascade to the detection of other enzymes, as well as proteins *via* ELISA techniques, is currently underway.

Conclusions

In summary, we have successfully developed a biosynthetic signal transduction and signal amplification methodology by utilising the selectivity and high activity of an enzyme, in combination with a water-tolerant organometallic catalyst. Through simple manipulation of the proligand trigger, this methodology can be applied towards the detection of a number of different enzymes as well as other analytes of interest. We have also shown that selective catalyst activation by an enzyme can be used to reduce a range of aldehydes allowing the amplification cascade to be tailored to the desired signal output. In principle, this technology could easily be used as a general signal amplification strategy for improving the sensitivity of enzyme detection assays and, by extension, protein detection assays through enzyme-linked immunosorbent assay (ELISA) protocols. Additionally, the ability for the system to process a simple input signal and convert it into an amplified signal output lends itself towards molecular computing applications as well as stimuli-responsive materials.

Acknowledgements

We would like to thank Atlas Genetics Ltd. for studentship funding (S.G.) and for the kind donation of a potentiostat. We would also like to acknowledge the extensive use of NMR and MS facilities within the Chemical Characterisation and Analysis Facility (CCAF) at the University of Bath for compound characterisation.

Notes and references

- 1 A. L. Lehninger, D. L. Nelson and M. M. Cox, *Lehninger Principles of Biochemistry*, W. H. Freeman, New York, 4th edn, 2004, ch. 12, pp. 421–439.
- 2 R. G. Macfarlane, *Nature*, 1964, **202**, 498.
- 3 G. Wald, *Science*, 1965, **150**, 1028.
- 4 J. M. Bowness, *Science*, 1966, **152**, 1370.
- 5 G. Krauss, *Biochemistry of Signal Transduction and Regulation*, Wiley-VCH, Weinheim, 3rd edn, 2008, ch. 3, pp. 115–149.
- 6 For reviews: (a) R. Yerushalmi, A. Scherz, M. E. van der Boom and H.-B. Kraatz, *J. Mater. Chem.*, 2005, **15**, 4480; (b) P. Theato, B. S. Sumerlin, R. K. O'Reilly and T. H. Epps III, *Chem. Soc. Rev.*, 2013, **42**, 7055; (c) J.-M. Lehn, *Angew. Chem., Int. Ed.*, 2015, **54**, 3276.
- 7 J. G. Millán and L. J. Prins, in *Supramolecular Systems in Biomedical Fields*, ed. H.-J. Schneider, The Royal Society of Chemistry, Cambridge, 2013, ch. 2, pp. 7–34.

- 8 P. Scrimin and L. J. Prins, *Chem. Soc. Rev.*, 2011, **40**, 4488.
- 9 (a) N. L. Rosi and C. A. Mirkin, *Chem. Rev.*, 2005, **105**, 1547; (b) X. Cao, Y. Ye and S. Liu, *Anal. Biochem.*, 2011, **417**, 1; (c) K. Saha, S. S. Agasti, C. Kim, X. Li and V. M. Rotello, *Chem. Rev.*, 2012, **112**, 2739; (d) J. Lei and H. Ju, *Chem. Soc. Rev.*, 2012, **41**, 2122.
- 10 S. W. Thomas III, G. D. Joly and T. M. Swager, *Chem. Rev.*, 2007, **107**, 1339.
- 11 (a) J. Liu and Y. Lu, *J. Am. Chem. Soc.*, 2003, **125**, 6642; (b) T. Takeuchi and S. Matile, *J. Am. Chem. Soc.*, 2009, **131**, 18048; (c) R. de la Rica and M. M. Stevens, *Nat. Nanotechnol.*, 2012, **7**, 821; (d) Z. Gao, L. Hou, M. Xu and D. Tang, *Sci. Rep.*, 2014, **4**, 3966.
- 12 (a) F. M. H. de Groot, C. Albrecht, R. Koekkoek, P. H. Beusker and H. W. Scheeren, *Angew. Chem., Int. Ed.*, 2003, **42**, 4490; (b) M. L. Szalai, R. M. Kewitch and D. V. McGrath, *J. Am. Chem. Soc.*, 2003, **125**, 15688; (c) R. J. Amir, N. Pessah, M. Shamis and D. Shabat, *Angew. Chem., Int. Ed.*, 2003, **42**, 4494.
- 13 M. Avital-Schmilovici and D. Shabat, *Soft Matter*, 2010, **6**, 1073.
- 14 (a) E. Sella and D. Shabat, *J. Am. Chem. Soc.*, 2009, **131**, 9934; (b) E. Sella, A. Lubelski, J. Klafter and D. Shabat, *J. Am. Chem. Soc.*, 2010, **132**, 3945.
- 15 (a) M. S. Baker and S. T. Phillips, *J. Am. Chem. Soc.*, 2011, **133**, 5170; (b) M. S. Baker and S. T. Phillips, *Org. Biomol. Chem.*, 2012, **10**, 3595.
- 16 (a) N. Karton-Lifshin and D. Shabat, *New J. Chem.*, 2012, **36**, 386; (b) K. Yeung, K. M. Schmid and S. T. Phillips, *Chem. Commun.*, 2013, **49**, 394; (c) M. Ikeda, T. Tanida, T. Yoshii, K. Kurotani, S. Onogi, K. Urayama and I. Hamachi, *Nat. Chem.*, 2014, **6**, 511; (d) T. Yoshii, S. Onogi, H. Shigemitsu and I. Hamachi, *J. Am. Chem. Soc.*, 2015, **137**, 3360; (e) H. Kim, M. S. Baker and S. T. Phillips, *Chem. Sci.*, 2015, **6**, 3388.
- 17 M. A. Swiderska and J.-L. Reymond, *Nat. Chem.*, 2009, **1**, 527.
- 18 O. V. Makhlynets and I. V. Korendovych, *Biomolecules*, 2014, **4**, 402.
- 19 (a) L. Zhu and E. V. Anslyn, *Angew. Chem., Int. Ed.*, 2006, **45**, 1190; (b) H. J. Yoon and C. A. Mirkin, *J. Am. Chem. Soc.*, 2008, **130**, 11590; (c) M. J. Wiester, P. A. Ulmann and C. A. Mirkin, *Angew. Chem., Int. Ed.*, 2011, **50**, 114.
- 20 L. Kovbasyuk and R. Krämer, *Chem. Rev.*, 2004, **104**, 3161.
- 21 (a) T. Abura, S. Ogo, Y. Watanabe and S. Fukuzumi, *J. Am. Chem. Soc.*, 2003, **125**, 4149; (b) J. M. McFarland and M. B. Francis, *J. Am. Chem. Soc.*, 2005, **127**, 13490; (c) N. D. McDaniel, F. J. Coughlin, L. L. Tinker and S. Bernhard, *J. Am. Chem. Soc.*, 2008, **130**, 210; (d) R. Kawahara, K. Fujita and R. Yamaguchi, *J. Am. Chem. Soc.*, 2010, **132**, 15108; (e) R. Kawahara, K. Fujita and R. Yamaguchi, *J. Am. Chem. Soc.*, 2012, **134**, 3643; (f) J. F. Hull, Y. Himeda, W.-H. Wang, B. Hashiguchi, R. Periana, D. J. Szalda, J. T. Muckerman and E. Fujita, *Nat. Chem.*, 2012, **4**, 383.
- 22 (a) X. Wu, J. Liu, X. Li, A. Zanotti-Gerosa, F. Hancock, D. Vinci, J. Ruan and J. Xiao, *Angew. Chem., Int. Ed.*, 2006, **45**, 6718; (b) X. Wu, X. Li, A. Zanotti-Gerosa, A. Pettman, J. Liu, A. J. Mills and J. Xiao, *Chem.-Eur. J.*, 2008, **14**, 2209; (c) J. Tan, W. Tang, Y. Sun, Z. Jiang, F. Chen, L. Xu, Q. Fan and J. Xiao, *Tetrahedron*, 2011, **67**, 6206; (d) Y. Wei, D. Xue, Q. Lei, C. Wang and J. Xiao, *Green Chem.*, 2013, **15**, 629.
- 23 D. R. van Staveren and N. Metzler-Nolte, *Chem. Rev.*, 2004, **104**, 5931.
- 24 (a) L. N. Jungheim and T. A. Shepherd, *Chem. Rev.*, 1994, **94**, 1553; (b) J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Järvinen and J. Savolainen, *Nat. Rev. Drug Discovery*, 2008, **7**, 255.
- 25 R. Noyori, M. Yamakawa and S. Hashiguchi, *J. Org. Chem.*, 2001, **66**, 7931.
- 26 S. Gnaïm and D. Shabat, *Acc. Chem. Res.*, 2014, **47**, 2970.
- 27 R. B. McComb, G. N. Bowers Jr and S. Posen, *Alkaline Phosphatase*, Plenum Press, New York, 1979.
- 28 D. Goltzman and D. Miao, *Encycl. Endocr. Dis.*, 2004, **1**, 164.
- 29 J. Ooi, K. Shiraki, Y. Morishita and T. Nobori, *J. Clin. Lab. Anal.*, 2007, **21**, 133.
- 30 G. Ramaswamy, V. R. Rao, L. Krishnamoorthy, G. Ramesh, R. Gomathy and D. Renukadevi, *Indian J. Clin. Biochem.*, 2000, **15**, 110.
- 31 G. M. M. Rao and L. O. Morghom, *Enzyme*, 1986, **35**, 57.
- 32 D. M. Kemeny and S. Chantler in *ELISA and Other Solid Phase Immunoassays*, ed. D. M. Kemeny and S. J. Challacombe, John Wiley & Sons, Chichester, 1988.
- 33 S. Goggins, C. Naz, B. J. Marsh and C. G. Frost, *Chem. Commun.*, 2015, **51**, 561.
- 34 D. G. Blackmond, *Angew. Chem., Int. Ed.*, 2009, **48**, 386.
- 35 (a) C. G. Bauer, A. V. Eremenko, E. Ehrentreich-Förster, F. F. Bier, A. Makower, H. B. Halsall, W. R. Heineman and F. W. Scheller, *Anal. Chem.*, 1996, **68**, 2453; (b) C. Ruan and Y. Li, *Talanta*, 2001, **54**, 1095.